Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of advanced head and neck squamous cell carcinoma in patients without human papillomavirus (HPV) infection. The designation recognizes the drug's potential to provide substantial improvements over existing therapeutic options for this patient population, which currently faces limited treatment alternatives.
The therapy is currently being evaluated in combination with Merck's Keytruda (pembrolizumab) in an ongoing Phase 3 clinical trial. This combination approach represents a multi-modal treatment strategy targeting different mechanisms of cancer cell proliferation and immune evasion. The Breakthrough Therapy Designation expedites the FDA's review process, potentially enabling faster patient access to the drug pending successful completion of clinical trials.
In related corporate developments, Johnson & Johnson extended its partnership with Trellus Health for patient support and access services through mid-2026. This agreement ensures continued assistance programs for patients requiring the company's specialty oncology medications during the critical period of ongoing clinical development and potential market expansion.